insights_auto
Why is 2X1 down 2.11%?
Dive Deeperchevron_right
2X1:ETR
Abivax SA
€78.80
arrow_downward
-2.11%(-1.70) 1D
Oct 7, 5:35:59 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
€78.90
High
€78.90
Low
€77.50
Mkt. cap
6.93B
Avg. vol.
1.73K
Volume
1.70K
52-wk high
€137.40
52-wk low
€60.85
EPS
-€5.20
No. of employees
98
Open
€78.90
High
€78.90
Low
€77.50
Mkt. cap
6.93B
Avg. vol.
1.73K
Volume
1.70K
52-wk high
€137.40
52-wk low
€60.85
EPS
-€5.20
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization
MarketBeat
·
17 hours ago
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com